{"id":207991,"name":"ASCENDIS PHARMA, INC.","slug":"ascendis-pharma-inc","state":"CA","country":"United States of America","description":"","totalSpending":2960000,"filings":23,"yearlySpending":[{"year":2020,"income":110000},{"year":2021,"income":500000},{"year":2022,"income":570000},{"year":2023,"income":590000},{"year":2024,"income":540000},{"year":2025,"income":650000}],"issues":["HCR","PHA"],"firms":["ASCENDIS PHARMA, INC."],"lobbyists":["CARY GIBSON","KATHY KULKARNI"],"govEntities":["Food & Drug Administration (FDA)","HOUSE OF REPRESENTATIVES","SENATE","Natl Institutes of Health (NIH)"],"sampleDescriptions":["Food and Drug Administration, Orphan Drugs","Food and Drug Administration, Orphan Drugs","Rare disease issues. Orphan drugs. Prescription Drug User Fee (PDUFA) reauthorization. Biosimilar User Fee Act (BsUFA) reauthorization. Food and Drug Administration facility inspections.","Rare disease issues. Orphan drugs. Prescription Drug User Fee (PDUFA) reauthorization. Biosimilar User Fee Act (BsUFA) reauthorization. Food and Drug Administration facility inspections.","Rare disease issues. Orphan drugs. Prescription Drug User Fee (PDUFA) reauthorization. Biosimilar User Fee Act (BsUFA) reauthorization. Cancer research."],"years":[2020,2021,2022,2023,2024,2025]}